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Suminary: The binding of [125I]insulin to isolated erythröcytes from diabetic children (n = 27) before (group
a) äs well äs one and five months after changing from porcine to biosynthetic human insulin (groups b and c)
was investigated. An analysis of variance of the binding parameters, determined by a nonlinear regression
procedure, yielded statistically significant differences between the receptor affinities Ka äs well äs between the
receptor concenträtions X0 of the groups a and b* a and c and b and c.
a b c
Ka ± sKa (1081/mol) 11.6 ± 7.6 19.3 ± 10.0 24.0 ± 4.5
i Xo + sXo (nmol/1) 0.068 ± 0.028 0.043 ± 0.030 0.029 ± 0.007
The resülts suggest that the change from porcine insulin to biosynthetic human insulin induces a short-term äs
well äs long-term increase in the affinity, and ä decrease in the coneentration of the erythrocyte insulin recep-
tors.
Insulinbindung an Erythrocyten vor und nach Umstellung von Schweine- auf biosynthetisches Humaninsulin
bei Kindern mit Typ-I-Diabetes
Zusammenfassung: Die Bindung von [125]Insuliri an Erythrocyten wurde bei diabetischen Kindern (n = 27)
vor (Gruppe a), einen sowie fünf Monate nach Umstellung von Schweineinsulin auf biosynthetisches Human-
insulin (Gruppen b und c) untersucht. Aus einer Varianzanalyse der mit einem nichtlinearen Regressionsver-
fehren ermittelten Bindungskenngrößen ergaben sich statistisch signifikante Unterschiede sowohl zwischen
den Rezeptoraffinitäten Ka als auch zwischen den Rezeptorkonzentrationen X0 der Gruppen a und b, a und c,
und b und c.
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a
11,6 ±7,6
0,068 ± 0,028
b
19,3 ± 10,0
0,043 ± 0,030
24,0 ± 4,5
0,029 ± 0,007
Ka ± sKa (1081/mol)
X0 ± sXo (nmol/1)
Die Resultate zeigen, daß die Umstellung von Sehweineihsulin auf biosynthetisches Humaninsulin sowohl
kurz- als auch langfristig eine Zunahme der Affinität und eine Abnahme der Konzentration der erythrocytä-
ren Insulinrezeptoren bewirkt.
Introduction
With the introduction of biosynthetic human insulin
into diabetes therapy, the question of the biological
activity of this new insulin arises, in particular in
comparison with the insulin pieparations used so far.
When analysing the insulin effect, the first step con-
sists in the binding to specific receptors on the cell
surface of the single target organs (1,2). This cou-
pling may be modulated by short-term change in the
receptor affinity and by long-term Variation of the
receptor conceniration (3,4).
In the in vitro studies to date, which only included
short-term alterations, no differences between the
binding properties of biosynthetic human insulin and
other insulins were revealed (5, 6, 7).
Therefore it was the objective of our investigations
to detect in vivo predominantly longer-term changes
in the binding behaviour of insulin to receptors after
switching from pork insulin to biosynthetic human
insulin.
The model of the erythrocyte insulin receptor was
selected, because the erythrocyte is subject to recep-
tor alterations similar to those occurring in the peri-
pheral tissues, and the small blood völume reqüired
can be technically and psychologically justified in
clinical studies.
The following data are the results of investigations
performed one and five months after switching the
insulin preparation.
Prior to the change (group a) all children had received an. iridivid-
ual raixture of regulär and NPH porcine insulin (Nordisk). They
were transferred to an individual mixture of regulär and NPH bio-
synthetic human insulin (Lilly); The binding studies were repeated
one month (group b).as well äs 5 months (group c) after ehanging
the insulin preparation.
The body height of all children was between the 25th and 75th
percentile; all children had normal weight corresponding to their
heights. Liver diseases and renal diseases äs well äs disturbances
of blood formation had been excluded by preliminary examina-
tioris.
Insulin binding studies
12 hours after the last insulin injectioh and the last food ingestion,
approximately 10 ml of heparinized whole blood were taken by
venipuncture.
Insulin binding was performed according to the procedure of
Gambhir (9) with slight modifications (10). Isolated erythrocytes
(3.5 - 4.5 x 10I2/1) were incubated with porcine [^25i]insulin
(0.05 nmol/1) and unlabeled porcine insulin (0.09 - 174 nmol/1)
at 15°C for 3 hours.
Analytical procedures
Free insulin and daily C-peptide excretion in urine wefe deter-
mined radioimmunologically (11, 12). HbA,ic values in blood
were measured according to I.e. (13).
Calculation procedures ' :'
For parariieter extraction a nonlinear regression procedure was
applied which is based on an algorithm indicated by Marquardt
(14). The insulin receptor affinity (Ka), the insulin receptor con-
centration (Xo), and the nonspecific binding (U) were iteratively
determined for the one-class binding model via the minimization
of the sum of the squares of erirpr with the aid of a HP 98 35 A
Computer.
For statistical analyses, parametric procedures (t-test for paired
data) were applied in cases of normal distributioh of the data;
otherwise nonparametric procedures (Wilcoxon^iest) were em-
ployed.
Materials and Methods
Subjects
Insulin binding to erythrocytes was measured in 27 children
($ 18, 6 9) aged between 12 and 18 years ( ± s, 15.33 ± 1.76
years) with type-I-diabetes. The duration of diabetes was between
2„7 und 14.9 years (x ±
 s> 7.48 ± 2.19 years), and the mean age
of diabetes manifestation was 8.2 years.
All children received two insulin injections per day, and the daily
insulin requirement was more than 0.5 lU/kg body weight
(0.86 ± 0.23, x ± s); i.e., all patients were in a phase of postre-
mission defmed by Akerbloom (8).
Results
One month after changing from porcine insulin to
biosynthetic human insulin the insulin receptor affin-
ity had significantty increased from 11.6 to 19.3 x
1081/mol (p < 0,001).
After another period of 4 months the receptor affini-
ty increased to 24.0 x l O8 1/mol, thus demonstrating
an incfease of 105.7% in comparison with the recep-
tor affinity priof to switching the insulin therapy
(fig. l, tabs. l and 2). > ?
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Fig. l Spccific insulin binding to human erythrocytes (4 χ 10Ι2/Ι)
in diabetic children bcfore (β), one month (A), and live
months (·) aftcr changing Insulin trcatment from porcine
to biosynthetic human insulin. Meansof [I25l]insulin bind-
ing (B/T) in dependence on the total insulin conccntration
(nmol/I) corrcctcd by iteratcd non-specific binding.
In contrast, the insulin receptor concentration de-
creased significantly within one month from 0.068 to
0.043 nmol/1 (p < 0.001). The second control exam-
ination showed a further decrease in the receptor
concentration to 0.029 nmol/I. This represents a
57.3% decrease compared with the receptor concen-
tration in patients under treatment with porcine in-
sulin (fig. l, tabs. l and 2).
The metabolic control of the diabetic children did
not exhibit any significant alterations within the ob-
servation period of 5 months. The HbA|C values
were in the r nge of 0.091, 0.091, and 0.089 (frac-
tion of total haemoglobin) (tab. 3).
The endogenous insulin secretion decreased from
0.83 to 0.29 nmol/24 h on average; the differences
in the C-peptide excretion in the 24-hour urine,
however, were statisticaliy not significant (tab. 3).
Tab. 1. Insulin receptor affmity (Ka ± SK.) and concentration(X„ ± s*») for three groups of children
Affinity (Ka) Concentration (X„)
(χ ± s) (χ ± s)
(10'1/mol) (nmol/I)
Group a
(porcine insulin)
Group b
(biosynthetic human
insulin, one month)
Groupc
(biosynthetic human
insulin, five months)
11.6± 7.6 0.068 ±0,028
19.3± 10.0 0.043 ±0.030
24.0 ± 4.5 0.029 ± 0.007
Tab. 2. Statistical comparison of insulin receptor affin i lies (Ka)
and concentrations (Xtf) for three groups of children
(n. s. — not significant).
Groups
xl
b Ka %
Xa
a
ρ < 0.001
p < 0.001
p < 0.001
p < 0.001
b
P
P
< 0.02
< 0.05
Discussion
In contrast to all reports to date (5, 6, 15), we were
able to demonstrate that the binding behaviour of
the insulin receptors changed characteristically after
switching from porcine insulin to biosynthetic human
insulin: Within 4 weeks the affinity constant in-
creased by 65% and the receptor concentration de-
creased by 36%. The second control investigation, 5
months after the switch, confirmed these results and
showed a further increase of the affinity constants by
Tab. 3. Fasting free insulin concentration, HbA|C values, daily insulin requirement and daily urinary C-peptide excretion for three
groups of diabetic children.
Group a
(porcine insulin)
Daily insulin requirement
(lU/kgbodyweight)
HbAic
(fraction of total haemoglobin)
Free insulin
(mU/1)
Daily urinary C-peptide excretion
(nmol/24 hours)
x
0.86
0.091
13.7
0.83
SD
±0.23
±0.018
±9.5
±0.72
Group b
(biosynthetic human
insulin, one month)
x
0.80
0.091
9.7
0.51
SD
±0.18
±0.019
±9.8
±0.60
Group c
(biosynthetic human
insulin, fivc months)
x
0.88 ±
0.089 ±
14.5 ±
0.29 ±
SD
0.18
0.022
10.0
0.26
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24% as well äs a decrease of the receptor concentra-
tion by 33%. We could exclude a deterioration of
metabolic control (16) as well as an increase in the
daily insulin requirement (17) as a cause for the
change in the binding behaviour in the children.
The lack of agreement with previously published re-
sults may possibly be explained by the fact that all in
vitro binding studies could only exclude shorMerm
changes in the binding behaviour and therefore are
not fully comparable with our study of 5 nionths du^
ration; the only in vivo study on the binding behav-
iour was performed with semisynthetic human insu-
lin on monocytes from only 6 adult type-I-diabetics
(15).
Within 4 weeks after switching to the treatment with
biosynthetic human insulin, the affinity constant in-
creased by 65% and the receptor concentratiön de-
creased by 36%. Since during the same period of
time only about 30% of the erythrocytes were newly
formed, this portion of new erythrocytes must have
been equipped with few, but unusually high-affinity
receptors, in order to give an explanation for the in-
crease in the affinity constants in the erythrocyte
population investigated. Furthermöre, this effect
should have induced after 5 months comparatively
much higher increases in the affinity as well as corre-
sponding decrease in the concentratiön than the data
obtained indicate.
The relatively rapid increase in affinity and the de-
crease in the receptor concentratiön after the switch
to biosynthetic human insulin therefore could not be
explained by the new synthesis of ä higher-affinity
receptor; it had to be caused by a direct or by a signal
molecule-mediated indirect modulation rnechanism
in which the biosynthetic human insulin interferes in
a modulatirig fashiön at the posttranslätionäl level.
Whether this process consists in the conformative al-
teration of aii uniform insulin receptör or in the se*
lectioning of a high-affinity receptor speeies cännot
be determined since a multif eceptor model as well as
the actually discussed negative cööperativity model
(18) or a two-receptor model (high affinity / low ca-
pacity — low affinity / high capacity) serve equally
well for the Interpretation of the binding data.
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